### Gilead and Galapagos Enter Transformative R&D Collaboration

**By the Numbers**

- **$3.95 B**
  - Gilead's upfront investment in Galapagos' pipeline

- **€140.59**
  - Per share price of Gilead's equity investment in Galapagos

- **$1.1 B**
  - Gilead to increase ownership of Galapagos via capital infusion

- **10 Years**
  - Duration of Gilead and Galapagos' collaboration

---

### ACCELERATES PROGRESS FOR BOTH COMPANIES

- Gilead receives an exclusive product license and option rights to develop and commercialize current and future Galapagos programs in all countries outside Europe
- Agreement will expand and accelerate future research and development efforts, while enabling Galapagos to preserve its innovative culture
- Gilead and Galapagos have complementary expertise and compatible scientific approaches that will accelerate innovation and progress

### BUILDS ON SUCCESSFUL FILGOTINIB COLLABORATION

- Plan to submit recently completed Phase 3 FINCH program in rheumatoid arthritis for regulatory approval in the U.S. and Europe by end of year
- Galapagos to participate more broadly in commercialization of filgotinib in Europe, accelerating the build out of the company’s commercial presence in Europe

### COMPELLING FINANCIAL INCENTIVES

- Gilead to make $3.95 billion upfront payment to access Galapagos’ innovation
- Gilead to invest $1.1 billion, increasing ownership to 22%
- Gilead and Galapagos will share future global development costs for filgotinib equally

---

“We are excited to enter into this unique agreement, which will generate both long-term strategic value and mutual, immediate benefits. We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team.”

— **Daniel O'Day**

Gilead’s Chairman and Chief Executive Officer

“Galapagos has been highly effective at target identification and drug discovery, progressing novel molecules from research into the clinic. We will benefit greatly from Gilead's expertise and infrastructure and believe this collaboration will provide an accelerated path to advance our pipeline.”

— **Onno van de Stolpe**

Galapagos’ Chief Executive Officer

---

ACCELERATING THE DELIVERY OF INNOVATIVE MEDICINE

For more information, visit www.gilead.com or www.glpg.com